GRTX Galera Therapeutics, Inc.
Price Chart
Executive Summary
Galera Therapeutics filed a Rule 425 communication reposting Obsidian Therapeutics' LinkedIn announcement of positive Phase 2 data for OBX-115 in advanced melanoma, showing a 67% objective response rate at the recommended Phase 2 dose. This data strengthens the strategic rationale for the pending merger between Galera and Obsidian, which is supported by a $350 million PIPE and will result in a combined company trading on Nasdaq under ticker OBX.
Actionable Insight
The strong Phase 2 data for OBX-115 significantly de-risks the combined entity's lead asset and increases the probability of merger completion. Traders should watch for the S-4 registration statement effectiveness and Galera stockholder vote timeline. The ASCO presentation on June 1, 2026, could drive further upside if additional detail emerges.
Key Facts
- OBX-115 achieved 67% ORR (10/15) at RP2D in advanced melanoma, including 2 complete responses
- Data presented at 2026 ASCO Annual Meeting in oral presentation
- No dose-limiting toxicities, no ICANS, no ICU transfers, and no treatment-related mortality observed
- Merger agreement dated April 14, 2026: Galera merges into Gazelle Parent alongside Obsidian
- Combined company will list on Nasdaq as Obsidian Therapeutics (ticker OBX)
- Concurrent $350 million PIPE financing supports the combined entity
Financial Impact
No financial figures disclosed in this filing; prior filings indicate a $350 million PIPE financing supporting the merger
Risk Factors
- Merger requires Galera stockholder approval and regulatory clearance
- OBX-115 is still investigational; Phase 3 data and FDA approval are years away
- Galera currently trades on OTC; Nasdaq listing is contingent on merger closing
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-235217 |
| Document: 0001193125-26-235217-index-headers.html | 0001193125-26-235217 |
| Document: 0001193125-26-235217-index.html | 0001193125-26-235217 |
| Document: 0001193125-26-235217.txt | 0001193125-26-235217 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 22, 2026
22d ago
|
425
| $0.1000 $0.1000 | · 0.00% | ▼ −1.66% | $0.0920 (−8.00%) |
|
May 19, 2026
24d ago
|
8-K
| $0.1010 $0.1000 | ▲ +0.99% | ▲ +2.79% | $0.0920 (+8.91%) |
|
Apr 22, 2026
7w ago
|
425
| $0.1000 $0.1000 | · 0.00% | ▼ −0.05% | $0.0920 (−8.00%) |
|
Apr 22, 2026
7w ago
|
425
| $0.1000 $0.1000 | · 0.00% | ▼ −0.05% | $0.0920 (−8.00%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $0.0790 $0.1020 | ▼ −29.11% | ▼ −27.72% | $0.0920 (−16.46%) |
|
Apr 14, 2026
8w ago
|
425
| $0.0790 $0.1020 | ▲ +29.11% | ▲ +27.72% | $0.0920 (+16.46%) |
|
Apr 14, 2026
8w ago
|
8-K
| $0.0790 $0.1020 | ▲ +29.11% | ▲ +27.72% | $0.0920 (+16.46%) |
|
Apr 3, 2026
10w ago
|
8-K
| $0.0410 $0.0420 | ▲ +2.44% | ▼ −1.70% | $0.0920 (+124.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access